Pharmaceuticals & Medical Research
LIST1012Related Stocks
News
Bio-Techne Acquired by Merck for $11.3 Billion at a Premium, Jumps Over 20% Premarket.
TradingKey - On June 25, Eastern Time, Germany's Merck Group announced that it will acquire US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.
Nuvalent Surges 39% Premarket. GSK Acquires for $10.6 Billion at 40% Premium, New CEO’s First Big Bet on Lung Cancer Field
TradingKey - British pharmaceutical giant GSK announced on June 9 that it will acquire U.S. biotechnology company Nuvalent (NUVL) for $10.6 billion in an all-cash deal to bolster its lung cancer drug pipeline. This transaction marks GSK's largest acquisition in over a decade and represents the first major strategic move under new CEO Luke Miels.
US Pre-Market: Three Major Index Futures Rise, Nasdaq Leads. Micron Rises Over 4%, Over 10 Billion Acquisition Drives Nuvalent to Surge Nearly 40%
TradingKey - On Tuesday Eastern Time, the three major U.S. stock index futures rose in pre-market trading as AI chip stocks extended their recovery rally. A temporary cooling of tensions in the Middle East led to a pullback in oil prices, boosting market risk appetite. As of press time, Dow futures
US Pre-Market: Chip Stocks Rebound Leads Nasdaq Futures, Marvell Surges Nearly 9% Pre-Market to Be Added to S&P 500
TradingKey - On Monday Eastern Time, all three major U.S. stock index futures rose in pre-market trading as technology stocks recovered from last week's sell-off, with a rebound in chip stocks leading gains in Nasdaq futures. However, escalating tensions in the Middle East pushed oil prices higher, and market concerns regarding inflationary pressures and the Federal Reserve's policy path persist. As of press time, Dow futures rose 0.36%, S&P 500 futures rose 0.83%, and Nasdaq futures rose 1.49%.
P3 Health Partners (PIII) Pullback: Is $12.38 a Re-Entry Buy Opportunity?
TradingKey - P3 Health Partners is at $12.38 after pulling back from $18.52 post-earnings high. Ascending trendline from $5.91 intact. Q1 net income +$3M vs -$44M prior year. EBITDA $26M. Target $14.16.
Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%
TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.
